ArticleThe Journal of international medical research2019
Survival of carbapenem-resistant
Article in The Journal of international medical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Colistin-based combination therapy versus monotherapy for carbapenem-resistant gram-negative bacterial infections: a systematic review and meta-analysis.Frontiers in cellular and infection microbiology · 2025Pooled it
- Efficiency of combination therapy versus monotherapy for the treatment of infections due to carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis.Systematic reviews · 2024Pooled it
- Perspectives on Colistin-An Old Antibiotic with Renewed Relevance in Modern Medicine.International journal of molecular sciences · 2026Review
- Carbapenem-Resistant Gram-Negative Bacteria: Mechanisms, Pathogen-Specific Strategies.Infection and drug resistance · 2026Review
- Multidrug-ResistantTropical medicine and infectious disease · 2025Article
- Integrative review on Acinetobacter baumannii as a multidrug-resistant pathogen: resistance mechanisms and therapeutic perspectives in the context of nosocomial infections.Revista da Sociedade Brasileira de Medicina Tropical · 2025Review
- A Tentative Clinical Study: Colistin Combined with Ceftazidime/Avibactam in the Treatment of Carbapenem-Resistant Gram-Negative Bacilli Infection.Infection and drug resistance · 2025Article
- Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-ResistantAntibiotics (Basel, Switzerland) · 2024Review
- Optimal dosing interval of intravenous Colistin monotherapy versus combination therapy: A systematic review and meta-analysis.European journal of translational myology · 2022Review
- Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-ResistantJournal of clinical medicine · 2022Review
- Article
- Rescuing the Last-Line Polymyxins: Achievements and Challenges.Pharmacological reviews · 2021Review
- Polymyxin Resistance Among XDR ST1 Carbapenem-ResistantFrontiers in microbiology · 2021Article
- A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.